HIV-1 Subtype C-Infected Individuals Maintaining High Viral Load as Potential Targets for the “Test-and-Treat” Approach to Reduce HIV Transmission

Vladimir Novitsky, Rui Wang, Hermann Bussmann, Shahin Lockman, Marianna K. Baum, Roger Shapiro, Ibou Thior, C. William Wester, Anthony Ogwu, Aida Asmelash, Rosemary Musonda, Adriana Campa, Sikhulile Moyo, Erik van Widenfelt, Madisa Mine, Claire Moffat, Mompati Mmalane, Joseph Makhema, Richard Marlink, Peter B. Gilbert, George R. Seage, Victor DeGruttola, Max EssexPLoS 2010 · DOI

Introduction

The "Test-and-Treat" strategy is a cornerstone of modern HIV prevention, positing that universal testing followed by immediate antiretroviral therapy (ART) can significantly curtail community-level transmission. The success of this approach hinges on identifying and treating individuals during their most infectious periods—specifically when plasma HIV-1 RNA levels (viral loads) are high.

While HIV-1 Subtype B is well-documented in Western contexts, Subtype C—the most prevalent global subtype and the dominant strain in Southern Africa—has less characterized viral load dynamics. This study analyzes HIV-1 Subtype C viral load distributions in Botswana to optimize the timing and frequency of "Test-and-Treat" interventions.

Methods

Researchers conducted a retrospective analysis using data from the Botswana–Harvard AIDS Institute Partnership, focusing on two primary objectives:

  1. Cross-sectional Analysis: Baseline viral loads were assessed for 4,348 drug-naïve individuals across seven cohorts, ranging from the general population to those initiating combination ART (cART).
  2. Longitudinal Analysis: Data from 42 "seroconverters" (individuals with estimated infection dates) were used to model viral load progression over time using cubic smoothing splines and Kaplan-Meier estimates.

The study defined "high viral load" as $\ge$ 50,000 copies/ml (4.7 $log_{10}$). Simulations were performed to evaluate the efficacy of 6-month versus 12-month testing intervals in identifying these high-viremia windows.

Datasets

The analysis utilized seven distinct cohorts from Botswana:

  • General Population/Natural History: Botsogo and Dikotlana studies.
  • Mother-to-Child Transmission (MTCT): Mashi and Mma Bana studies.
  • Treatment-Initiating (cART): Tshepo, Mashi Plus, and Bomolemo studies.
  • Primary Infection: The Tshedimoso study provided longitudinal data for the seroconverter group.

Results

Viral Load Distribution and Heterogeneity

The study found a significant gap in median viral loads between populations. In general population cohorts, median levels ranged from 4.1 to 4.2 $log_{10}$, with 24%–28% of individuals exhibiting high viral loads. In contrast, treatment-seeking cohorts showed median levels of 5.1 to 5.3 $log_{10}$, with 65%–83% of individuals exceeding the 50,000 copies/ml threshold. Notably, men in the general population cohorts tended to have higher viral loads than women.

Duration of High Infectivity

Longitudinal analysis revealed a "high-transmitter" phenotype: approximately 33% (95% CI: 20%–50%) of individuals maintain a viral load $\ge$ 50,000 copies/ml for at least 180 days post-seroconversion. The median duration of this highly infectious state was 350 days (IQR: 269–428).

Impact of Testing Intervals

Modeling suggests that a 6-month testing interval is a critical "sweet spot." This frequency could identify all individuals maintaining high viral loads and, assuming immediate treatment initiation, reduce the period of high transmissibility by 77% (95% CI: 71%–82%). In comparison, a 12-month interval was significantly less effective, reducing the high-transmissibility window by only 56%.

Discussion and Implications

These findings suggest that a subset of the population contributes disproportionately to the HIV epidemic by maintaining high viral loads for extended periods. Targeting these individuals through frequent, repeated testing could be a highly effective public health strategy.

Limitations

The study's longitudinal findings are based on a relatively small sample of 42 seroconverters. Furthermore, the model assumes immediate treatment initiation and 100% efficacy in stopping transmission, which may not account for real-world barriers such as drug resistance or suboptimal adherence. Future research should also investigate behavioral drivers of transmission and potential gender-based differences in viral dynamics.

Summary updated

Abstract

The first aim of the study is to assess the distribution of HIV-1 RNA levels in subtype C infection. Among 4,348 drug-naïve HIV-positive individuals participating in clinical studies in Botswana, the median baseline plasma HIV-1 RNA levels differed between the general population cohorts (4.1-4.2 log(10)) and cART-initiating cohorts (5.1-5.3 log(10)) by about one log(10). The proportion of individuals with high (> or = 50,000 (4.7 log(10)) copies/ml) HIV-1 RNA levels ranged from 24%-28% in the general HIV-positive population cohorts to 65%-83% in cART-initiating cohorts. The second aim is to estimate the proportion of individuals who maintain high HIV-1 RNA levels for an extended time and the duration of this period. For this analysis, we estimate the proportion of individuals who could be identified by repeated 6- vs. 12-month-interval HIV testing, as well as the potential reduction of HIV transmission time that can be achieved by testing and ARV treating. Longitudinal analysis of 42 seroconverters revealed that 33% (95% CI: 20%-50%) of individuals maintain high HIV-1 RNA levels for at least 180 days post seroconversion (p/s) and the median duration of high viral load period was 350 (269; 428) days p/s. We found that it would be possible to identify all HIV-infected individuals with viral load > or = 50,000 (4.7 log(10)) copies/ml using repeated six-month-interval HIV testing. Assuming individuals with high viral load initiate cART after being identified, the period of high transmissibility due to high viral load can potentially be reduced by 77% (95% CI: 71%-82%). Therefore, if HIV-infected individuals maintaining high levels of plasma HIV-1 RNA for extended period of time contribute disproportionally to HIV transmission, a modified "test-and-treat" strategy targeting such individuals by repeated HIV testing (followed by initiation of cART) might be a useful public health strategy for mitigating the HIV epidemic in some communities.
BibTeX
@inproceedings{novitsky2010hiv,
  author = {Vladimir Novitsky and Rui Wang and Hermann Bussmann and Shahin Lockman and Marianna K. Baum and Roger Shapiro and Ibou Thior and C. William Wester and C. William Wester and Anthony Ogwu and Aida Asmelash and Rosemary Musonda and Adriana Campa and Sikhulile Moyo and Erik van Widenfelt and Madisa Mine and Claire Moffat and Mompati Mmalane and Joseph Makhema and Richard Marlink and Peter B. Gilbert and George R. Seage and Victor DeGruttola and Max Essex},
  title = {{HIV-1 Subtype C-Infected Individuals Maintaining High Viral Load as Potential Targets for the “Test-and-Treat” Approach to Reduce HIV Transmission}},
  booktitle = {PLoS},
  year = {2010},
  doi = {10.1371/journal.pone.0010148},
}
Figure